A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets

European Journal of Neuroscience

Volumn 21, Issue 4, 2005, Pages 841-854

  Iravani, Mahmoud M ^a   Syed, Emilie ^a   Jackson, Michael J ^a   Johnston, Louisa C ^a   Smith, Lance A ^a   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Common marmosets; MPTP; Parkinson's disease; Partial lesion; Striatum; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CALBINDIN; LEVODOPA; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; MARMOSET; MOTOR PERFORMANCE; NERVE DEGENERATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; REPRODUCIBILITY; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BEHAVIOR, ANIMAL; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; CALLITHRIX; CORPUS STRIATUM; DISABILITY EVALUATION; DISEASE MODELS, ANIMAL; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; IMMUNOHISTOCHEMISTRY; LEVODOPA; MALE; MOTOR ACTIVITY; NEURONS; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 16244387184     PISSN: 0953816X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2005.03915.x     Document Type: Article

References (43)

1. Alexander, G.M., Schwartzman, R.J., Brainard, L., Gordon, S.W. & Grothusen, J.R. (1992) Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Brain Res., 588, 261-269.
2. Betarbet, R., Turner, R., Chokkan, V., DeLong, M.R., Allers, K.A., Walters, J., Levey, A.L. & Greenamyre, J.T. (1997) Dopaminergic neurons intrinsic to the primate striatum. J. Neurosci., 17, 6761-6768.
3. Bezard, E., Dovero, S., Prunier, C., Ravenscroft, P., Chalon, S., Guilloteau, D., Crossman, A.R., Bioulac, B., Brotchie, J.M. & Gross, C.E. (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetra- hydropyridine-lesioned macaque model of Parkinson's disease. J. Neurosci., 21, 6853-6861.
4. Bezard, E., Gross, C.E. & Brotchie, J.M. (2003) Presymptomatic compensation in Parkinson's disease is not dopamine mediated. Trends Neurosci., 26, 215-221.
5. Brooks, D.J., Ibanez, V., Sawle, G.V., Quinn, N., Lees, A.J., Mathias, C.J., Bannister, R., Marsden, C.D. & Frackowiak, R.S. (1990) Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann. Neurol., 28, 547-555.
6. Damier, P., Hirsch, E.C., Agid, Y. & Graybiel, A.M. (1999a) The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain, 122, 1437-1448.
7. Damier, P., Hirsch, E.C., Agid, Y. & Graybiel, A.M. (1999b) The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D (28K) immunohistochemistry. Brain, 122, 1421-1436.
8. Dass, B., Iravani, M.M., Jackson, M.J., Engber, T.M., Galdes, A. & Jenner, P. (2002) Behavioural and immunohistochemical changes following supranigral administration of sonic hedgehog in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated common marmosets. Neuroscience, 114, 99-109.
9. Elsworth, J.D., Deutch, A.Y., Redmond, D.E. Jr, Taylor, J.R., Sladek, J.R. Jr & Roth, R.H. (1989) Symptomatic and asymptomatic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates: biochemical changes in striatal regions. Neuroscience, 33, 323-331.
10. Falardeau, P., Bedard, P.J. & Di Paolo, T. (1988) Relation between brain dopamine loss and D2 receptor density in MPTP monkeys. Neurosci. Lett., 86, 225-229.
11. Fearnley, J.M. & Lees, A.J. (1991) Aging and Parkinson's disease: substantion nigra regional selectivity. Brain, 114, 2283-2301.
12. Forno, L.S., DeLanney, L.E., Irwin, I. & Langston, J.W. (1994) Evolution of nerve fiber degeneration in the striatum in the MPTP-rreated squirrel monkey. Mol. Neurobiol., 9, 163-170.
13. Gerfen, C.R., Baimbridge, K.G. & Thibault, J. (1987) The neostriatal mosaic: III biochemical and developmental dissociation of patch-matrix mesostriatal systems. J. Neurosci., 1, 3935-3944.
14. Gibb, W.R. & Lees, A.J. (1991) Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry, 54, 388-396.
15. Graybiel, A.M., Hirsch, E.C. & Agid, Y.A. (1987) Differences in tyrosine hydroxylase-like immunoreactivity characterizes the mesostriatal innervation of striosomes and extrastriosomal matrix at maturity. Proc. Natl Acad. Sci. USA, 84, 303-307.
16. Hanrraye, P., Varastet, M., Peschanski, M., Riche, D., Cesaro, P., Wilier, J.C. & Maziere, M. (1993) Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience, 53, 169-178.
17. Iravani, M.M., Costa, S., Tel Jackson, M.J.B.C., Cannizzaro, C., Pearce, R.K. & Jenner, P. (2001) GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets. Eur. J. Neurosci., 13, 597-608.
18. Iravani, M.M., Jackson, M.J., Kuoppamaki, M., Smith, L.A. & Jenner, P. (2003) 3,4-Methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalises locomotor activity in parkinsonian primates. J. Neurosci., 23, 9107-9115.
19. Jenner, P. (2003) MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology, 61 (6 Suppl. 3), S4-S11.
20. Jenner, P. & Marsden, C.D. (1986) The actions of 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. J. Neural Transm., 20 (Suppl.), 11-39.
21. Jenner, P., Zeng, B.Y., Smith, L.A., Tel Pearce, R.K.B., Chancharme, L. & Moachon, G. (2000) Antiparkinsonian and neuroprotective effects of modafinil in the MPTP-rreated common marmoset. Exp. Brain Res., 133, 178-188.
22. Kish, S.J., Shannak, K. & Hornykiewicz, O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med., 318, 876-880.
23. Kopin, I.J. & Markey, S.P. (1988) MPTP toxicity: implications for research in Parkinson's disease. Annu. Rev. Neurosci., 11, 81-96.
24. Marino, M.J., Valenti, O. & Conn, P.J. (2003) Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging, 20, 377-397.
25. McBride, J.L. & Kordower, J.H. (2002) Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. Prog. Brain Res., 138, 421-432.
26. Moratalla, R., Quinn, B., DeLanney, L.E., Irwin, I., Langston, J.W. & Graybiel, A.M. (1992) Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl Acad. Sci. USA, 89, 3859-3863.
27. Perez-Otano, I., Oset, C., Luquin, M.R., Herrero, M.T., Obeso, J.A. & Del Rio, J. (1994) MPTP-induced parkinsonism in primates: pattern of striatal dopamine loss following acute and chronic administration. Neurosci. Lett., 175, 121-125.
28. Pifl, C. Schingnitz, G. & Hornykiewicz, O. (1988) The neurotoxin MPTP does not reproduce in the rhesus monkey the interregional pattern of striatal dopamine loss typical of human idiopathic Parkinson's disease. Neurosci. Lett., 92, 228-233.
29. Pifl, C., Schingnitz, G. & Hornykiewicz, O. (1991) Effect of 1-methyl-4-phenyl-1,2,3,6-terrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience, 44, 591-605.
30. Porritt, M.J., Batchelor, P.E., Hughes, A.J., Kalnins, R., Donnan, G.A. & Howells, D.W. (2000) New dopaminergic neurones in Parkinson's disease striatum. Lancet, 356, 44-45.
31. Prensa, L., Cossette, M. & Parent, A. (2000) Dopaminergic innervation of human basal ganglia. J. Chem. Neuroanat., 20, 207-213.
32. Robinson, I.E., Mocsary, Z., Camp, D.M. & Whishaw, I.Q. (1994) Time couse of recovery of extracellular dopamine following partial damage to the nigrostriatal dopamine system. J. Neurosci., 14, 2687-2696.
33. Schapira, A.H. (2002) Dopamine agonists and neuroprotection in Parkinson's disease. Eur. J. Neurol., 9 (Suppl. 3), 7-14.
34. Shults, C.W., Oakes, D., Kieburtz, K., Beal, M.F., Haas, R., Plumb, S., Juncos, J.L., Nutt, J., Shoulson, L, Carter, J., Kompoliti, K., Perlmutter, J.S., Reich, S., Stern, M., Watts, R.L., Kurlan, R., Molho, E., Harrison, M., Lew, M. & Parkinson Study Group. (2002) Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol., 59, 1541-1550.
35. Sirinathsinghji, D.J., Kupsch, A., Mayer, E., Zivin, M., Pufal, D. & Oertel, W.H. (1992) Cellular localization of tyrosine hydroxylase mRNA and cholecystokinin mRNA-containing cells in the ventral mesencephalon of the common marmoset: effects of 1 methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Brain Res. Mol Brain Res., 12, 267-274.
36. Snow, B.J., Vingerhoets, F.J., Langston, J.W., Tetrud, J.W., Sossi, V. & Calne, D.B. (2000) Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonism. J. Neurol. Neurosurg. Psychiatry, 68, 313-316.
37. Song, D.D. & Haber, S.N. (2000) Striatal responses to partial dopaminergiclesion: evidence for compensatory sprouting. J. Neurosci., 20, 5102-5114.
38. Stephan, B., Baron, G. & Schwerdtfeger, W.K. (1980) The Brain of Common Marmoset: a Stereotaxic Atlas. Springer-Verlag, Berlin.
39. Vingerhoets, F.J., Snow, B.J., Tetrud, J.W., Langston, J.W., Schulzer, M. & Calne, D.B. (1994) Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions. Ann. Neurol., 36, 765-770.
40. Wang, L.H., Besirli, C.G. & Johnson, E.M. Jr (2004) Mixed-lineage kinases: a target for the prevention of neurodegeneration. Annu. Rev. Pharmacol. Toxicol., 44, 451-474.
41. Waters, C.M., Hunt, S.P., Jenner, P. & Marsden, C.D. (1987) An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridme in the marmoset. Neuroscience, 23, 1025-1039.
42. Youdim, M.B. & Weinstock, M. (2004) Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Neurotoxicology, 25, 243-250.
43. Zigmond, M.J., Abercrombie, E.D., Berger, T.W., Grace, A.A. & Stricker, E.M. (1990) Compensation after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci., 13, 290-296.